ReviewCureus2025
Advancing Care in Alzheimer's Disease: Current Treatments and Their Impact on Quality of Life.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ELAVL Proteins, miRNA Fate, and Extracellular RNA Communication in Brain Aging and Neurodegeneration.Cells · 2026Review
- Neuroprotective Effects of Two N-Benzylamides in Models of Oxidative Stress, Neurite Outgrowth and Neurodegeneration.Oxidative medicine and cellular longevity · 2026Article
- Synergistic Neuroprotection in Tauopathic Mice via Green-Synthesized Silver Nanoparticles Co-delivering Methylene Blue and Moringa oleifera.Molecular neurobiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory deficits and cognitive decline. It is currently the most common cause of dementia globally and carries a significant disease burden, given the rising aging population worldwide. Although AD is debilitating for the patient, the complex nature of the disease is also a source of tremendous mental distress for caregivers. Finding, understanding, and evaluating the best treatments can be challenging and overwhelming when coping with a life-changing diagnosis of AD. Although there is currently no definite cure for AD, all the discussed treatments aim to improve a patient's quality of life and attenuate the time spent in disability. This study compiles and discusses the risks, benefits, and efficacy of all currently available treatments for AD, including treatments that target the control of cognitive and non-cognitive symptoms. Additionally, the manuscript discusses investigational therapeutics, including small molecules and immunotherapies in phase 2 or 3 clinical trials, and assesses non-pharmacological interventions that may alleviate disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.